美国胸科学会年会(ATS)将于2024年5月17日至5月22日在美国圣地亚哥举行,本届ATS年会主题为“Breakthrough Research, Excellence in Patient Care”,届时将有超过万名来自全球各地的医学专家和科学家参与其中,一同探讨全球范围内呼吸领域的最新研究进展,推动学科发展。 本期内容精选2024年ATS国际大会中15场生物制剂相关的重点研究和前沿知识,与您共享。 1.会议时间:2024/05/20,00:15-02:15,专题海报展 嗜酸性肉芽肿性多血管炎(EGPA)中的肺部受累和持续性肺损伤:对美国医疗保险索赔数据的回顾性分析Pulmonary Involvement and Persistent Pulmonary Damage in Eosinophilic Granulomatosis With Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data2.会议时间:2024/05/20,02:30-04:15,专题海报展 De-escalation of Asthma Therapy After Initiation of Biologics for Severe Asthma in an Ambulatory Setting3.会议时间:2024/05/20,02:30-03:30,专家访谈 BIOLOGIC THERAPIES IN SEVERE ASTHMA: WHICH AGENT FOR WHAT PATIENT4.会议时间:2024/05/20,05:39-05:58,儿科年度回顾 Precision Medicine in Asthma: Omics and Biologics5.会议时间:2024/05/20,06:27-06:39,小型研讨会 在GINA 4和GINA 5哮喘严重程度中是否存在肺血管差异?Are There Pulmonary Vascular Differences in GINA 4 and GINA 5 Asthma Severity?6.会议时间:2024/05/21,00:51-01:03,小型研讨会 哮喘患者高气道TSLP与更严重的疾病及多种2型炎症生物标志物相关High Airway TSLP Levels in Asthma Associate With More Severe Disease and Multiple Biomarkers of Type 2 Inflammation7.会议时间:2024/05/22,02:30-04:15,专题海报展 在美国重度哮喘成人中,长期全身性糖皮质激素治疗增加了死亡率:CHRONICLE研究结果Mortality Among US Adults With Severe Asthma Is Increased With Maintenance Systemic Corticosteroid Treatment: Results From the CHRONICLE Study8.会议时间:2024/05/22,02:30-04:15,专题海报展 ⭐️3期MANDARA研究开放标签延长期间本瑞利珠单抗治疗嗜酸性粒细胞肉芽肿性多血管炎的安全性Safety of Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis During the Open-label Extension Period of the Phase 3 MANDARA Study9.会议时间:2024/05/22,02:30-04:15,专题海报展 ⭐️3期MANDARA研究中美泊利珠单抗与本瑞利珠单抗对嗜酸性粒细胞肉芽肿性多血管炎治疗中的嗜酸性粒细胞清除作用The Effect of Benralizumab Versus Mepolizumab on the Depletion of Eosinophils in the Treatment of Eosinophilic Granulomatosis With Polyangiitis During the Phase 3 MANDARA Study10.会议时间:2024/05/22,02:30-04:15,专题海报展 ⭐️生物制剂对哮喘中2型炎症生物标志物的影响:文献综述Effect of Biologics on Biomarkers of Type 2 Inflammation in Asthma: A Review of the Literature11.会议时间:2024/05/22,02:30-04:15,专题海报展 抗IL-5和抗IL-5rα在重度支气管哮喘中的疗效差异The Difference in the Effectiveness of Anti-IL-5 Antibodies and Anti-IL-5rα Antibodies in Severe Bronchial Asthma12.会议时间:2024/05/22,02:30-04:15,专题海报展 Tezepelumab作为重度哮喘患者初始生物制剂选择的真实经验A Real-world Experience With Tezepelumab as the First Biologic Option in Severe Asthma Patients13.会议时间:2024/05/22 02:30-04:15,专题海报展 ⭐️中国真实世界调查显示在哮喘严重程度和哮喘控制方面,临床实践与指南之间的差距Gaps in Asthma Severity and Asthma Control Between Clinical Practice and Guideline According to a Real-World Survey in China14.会议时间:2024/05/22,05:55-06:15,科学研讨会 Can We Achieve Remission and Disease Modification in Severe Asthma Patients?15.会议时间:2024/05/22,04:15-07:15,海报讨论会 Biologics Use and Switch Patterns in the French Severe Asthma Cohort本文来源:呼吸e声 责任编辑:Lin *'医学界'力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
|